Velphoro (sucroferric oxyhydroxide) / Fresenius Kabi, Kissei, CSL Behring - LARVOL DELTA

Integrative Analysis of Drug Co-Prescriptions in Peritoneal Dialysis Reveals Molecular Targets and Novel Strategies for Intervention. (PubMed, J Clin Med) - " We found commonly prescribed drugs such as furosemide, sucroferric oxyhydroxide, calcitriol, darbepoetin alfa, and aluminum hydroxide to be integral components of PD patient management, prescribed in over 30% of PD patients. The molecular-network-based approach found combinations of drugs like theophylline, fluoxetine, celecoxib, and amitriptyline to possibly have synergistic effects and to target dysregulated molecules of PD-related pathomechanisms. Two further distinct categories of drugs emerged as particularly interesting in our study: selective serotonin reuptake inhibitors (SSRIs), which were found to modulate molecules implicated in peritoneal fibrosis, and vascular endothelial growth factor (VEGF) inhibitors, which exhibit anti-fibrotic properties that are potentially useful for PD. This comprehensive exploration of drug co-prescriptions in the context of PD-related pathomechanisms provides valuable insights for opening future therapeutic strategies and..."

Journal • Fibrosis • Immunology • Renal Disease

Management of Resistant Hyperphosphatemia in Maintenance Hemodialysis (MHD) patients - Role of Sucroferric Oxyhydroxide (SFO): A prospective study (ERA 2025) - "Background and Aims:Hyperphosphatemia is common in advanced CKD and is associated with increased cardiovascular morbidity, bone mineral abnormalities and mortality. SFO demonstrated superior efficacy in reducing serum phosphorus levels in MHD patients who previously failed to achieve phosphorus control with sevelamer carbonate in tolerated doses. SFO offered a better phosphorus control (p = 0.03), numerically lower mean daily pill burden (p = 0.02), lower treatment cost and a better treatment adherence than sevelamer carbonate. These findings strongly support the use of SFO as first line hyperphosphatemic patients with advanced CKD to improve phosphorus control, patient longevity and Quality of life."

Clinical • Cardiovascular • Chronic Kidney Disease • Metabolic Disorders • Nephrology • Renal Disease

Indirect evaluation of bone metabolism in dialysis: do we all have the same bones? (ERA 2025) - "We analyzed demographic data (Date of birth, gender, blood type), comorbidities (Diabetes, hypertension), dialysis data (type of dialysis technique, dialytic age), blood tests (calcium, phosphate, Parathormone, Vitamin D), therapies (magnesium aluminate, calcium carbonate, sevelamer, sucroferric oxyhydroxide, lantanium carbonate, cholecalciferol, calcitriol, paracalcitol, cinacalcet, etelcalcetide) and fractures. In our analysis, we did not find any differences among the treatments for CKD-MBD to which the patients were subjected during the observed period. Our data suggest that, although preclinical studies and early stages of CKD showed that ADPKD patients exhibit distinct bone mineral disorders, no differences in treatment are observed in dialysis patients. Our data even confirm that there is no difference in fracture risk among hemodialysis patients."

Autosomal Dominant Polycystic Kidney Disease • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Genetic Disorders • Hypertension • Metabolic Disorders • Musculoskeletal Diseases • Nephrology • Orthopedics • Polycystic Kidney Disease • Renal Disease

Tenapanor administration combined with phosphate binders provides synergistic phosphate lowering effect (ERA 2025) - "Six types of P binders had been used in Group Ad (sevelamer hydrochloride, bixalomer, calcium carbonate, ferric citrate, sucroferric oxyhydroxide hydrate and lanthanum carbonate hydrate). Oral administration of tenapanor significantly reduced P adsorption and improved serum P level in patients undergoing HD either when it was administrated alone or adding on P binders. This P absorption reduction effect of tenapanor was greatly enhanced when it was added on P binders. The mechanism of this synergistic effect would be an important research question."

Metabolic Disorders • Nephrology • Renal Disease

Comparison of the efficacy of sucroferric oxyhydroxide and lanthanum carbonate in the hyperphosphatemia of maintainable Hemodialysis. (PubMed, BMC Pharmacol Toxicol) - "SFOH was superior to LC in lowering patients' blood phosphorus and iPTH levels in patients with maintenance hemodialysis hyperphosphatemia combined with secondary hyperparathyroidism."

Journal • Endocrine Disorders • Metabolic Disorders • Nephrology • Renal Disease • Secondary Hyperparathyroidism

Ferric Carboxymaltose Versus Iron Sucrose for Treating Anemia in Pregnant Women (clinicaltrials.gov) - P4 | N=60 | Completed | Sponsor: CMH Multan Institute of Medical Sciences

New P4 trial • Anemia • Hematological Disorders

Short- term effect of sucroferric oxyhydroxide on phosphorus reduction in end -stage renal disease patients with hyperphosphatemia (ChiCTR) - P=N/A | N=61 | Completed | Sponsor: Ningbo First Hospital; Ningbo First Hospital

New trial • Chronic Kidney Disease • Metabolic Disorders • Nephrology • Renal Disease

Effects of Shape on the Disintegration Time and Friability of Sucroferric Oxyhydroxide-Containing Mini-Tablets. (PubMed, Chem Pharm Bull (Tokyo)) - "A cup depth/diameter of 0.2 was identified as optimal for minimizing the friability of mini-tablets and can be implemented in commercial production without issues. In conclusion, tablet shape should be carefully considered during the development of mini-tablets to ensure low friability."

Journal • Chronic Kidney Disease • Metabolic Disorders • Nephrology • Renal Disease

Management of serum phosphorus over six months in hemodialysis patients: a comparison of sucroferric oxyhydroxide (SO) monotherapy and tenapanor with other non-SO phosphate binders (NKF-SCM 2025) - "However, the SO group had fewer pills (4.7 pills for SO vs 9.7 pills for +TN group at M6), and less diarrhea during fup (20.4% at bl, 23.9% at fup, p=0.19 for SO group; 21.9% at bl, 33.9% at fup, p=0.01 for +TN group).Conclusion For HD pts with sP > 7 mg/dL despite treatment with non-SO monotherapy, switching to SO monotherapy or adding TN resulted in comparable sP reductions, over 6 months. However, pts on SO monotherapy had less than half the PB pill burden, and lower % of diarrhea, compared to those adding TN."

Clinical • Monotherapy • Metabolic Disorders • Nephrology • Renal Disease

Efficacy and Safety of Phosphate-Lowering Agents for Adult Patients with Chronic Kidney Disease Requiring Dialysis: A Network Meta-Analysis. (PubMed, Clin J Am Soc Nephrol) - "Compared with calcium-based agents, sevelamer was associated with lower all-cause mortality, and sucroferric oxyhydroxide and lanthanum were associated with slower progression of CACS. Potential benefits and harms should be considered when selecting phosphate-lowering agents (PROSPERO: CRD42022328388)."

Journal • Retrospective data • Cardiovascular • Chronic Kidney Disease • Gastrointestinal Disorder • Musculoskeletal Diseases • Nephrology • Renal Disease

All That Opaques is Not Metal (ACG 2024) - "Pathologic evaluation concluded them to be pills, and an investigation of his prescribed medications determined them to be Sucroferric oxyhydroxide (Velphoro). Although these pills are less than 2.5 cm, if they have been present for several days, endoscopic evaluation may be necessary to assess the surrounding erosive mucosal damage. Other compounds that can be radiopaque include certain potassium preparations, calcium carbonate, iodinated compounds, acetazolamide, and busulfan, among others."

Back Pain • Gastrointestinal Disorder • Metabolic Disorders • Musculoskeletal Pain • Nephrology • Pain • Renal Disease

In Vitro Study on Combined Effect of Drugs for Hyperphosphatemia on Phosphorus Adsorption Capacity. (PubMed, Chem Pharm Bull (Tokyo)) - "Precipitated calcium carbonate (CC), ferric citrate hydrate (FC), lanthanum carbonate hydrate (LC), and sucroferric oxyhydroxide (SO) were used as phosphorus binders. In contrast, the adsorption capacities of CC + FC and FC + LC decreased in the 1st and 2nd fluid compared with that when used alone because of the release of citrate ions that chelate calcium or lanthanum ions. These results suggest that SO is less affected by interactions with other phosphorus binders and changes in pH and may be suitable for patients receiving concomitant drugs."

Journal • Preclinical • Metabolic Disorders • Nephrology • Renal Disease

Colon Collectibles: Unearthing Coin-Shaped Treasures in Kidney Disease (KIDNEY WEEK 2024) - "Due to its insoluble iron content, unchewed sucroferric oxyhydroxide tablets appear as highly radio-opaque round objects on imaging. Understanding the properties and absorption mechanisms of such medications, coupled with thorough patient history-taking, can mitigate the need for invasive interventions and guide appropriate management strategies."

Nephrology • Renal Disease

A Postmarketing Study Assessing Safety and Efficacy of Velphoro in Korean Adult Dialysis Patients (KIDNEY WEEK 2024) - "In this PMS, GI disorders were the main ADR. No obvious iron accumulation was observed. In conclusion, Velphoro® has a favourable safety and tolerability profile in Korean patients that is consistent with that observed in Phase 3 trial (PA-CL-05A)."

Clinical • P4 data • Chronic Kidney Disease • Gastroenterology • Gastrointestinal Disorder • Metabolic Disorders • Nephrology • Pain

Managing Hyperphosphatemia in Patients on Hemodialysis: A Comparison of Sucroferric Oxyhydroxide (SO) Monotherapy and Tenapanor with Other Non-SO Phosphate Binders (KIDNEY WEEK 2024) - "For HD pts who had sP > 7 mg/dL despite treatment with non-SO monotherapy, switching to SO monotherapy or adding TN resulted in comparable reductions in sP. However, pts with SO monotherapy had less than half the PB pill burden, compared to those adding TN."

Clinical • Monotherapy • Metabolic Disorders • Nephrology • Renal Disease

Efficacy and safety of sucroferric oxyhydroxide versus sevelamer carbonate: A systematic review and meta-analysis. (PubMed, Hemodial Int) - "This meta-analysis of randomized trials showed that both drugs, sucroferric oxyhydroxide and sevelamer equally and effectively controlled serum phosphorus levels, whereas sucroferric oxyhydroxide revealed a better profile in terms of gastrointestinal adverse events. Sucroferric oxyhydroxide is a valuable option for patients receiving KRT when sevelamer carbonate is more difficult to tolerate."

Clinical • Journal • Retrospective data • Review • Chronic Kidney Disease • Gastrointestinal Disorder • Nephrology • Orthopedics • Renal Disease

A Multicenter, Real-world Study of Sucroferric Oxyhydroxide (Velphoro) to Treat Hyperphosphatemia in Chinese Adult CKD Patients on Dialysis (ChiCTR) - P=N/A | N=10000 | Not yet recruiting | Sponsor: Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University

New trial • Real-world • Real-world evidence • Chronic Kidney Disease • Metabolic Disorders • Nephrology • Renal Disease • FGF23

The Use of Sucroferric Oxyhydroxide Prior to Sigmoidoscopy in Patients With End-Stage Kidney Disease: A Case Report. (PubMed, Can J Kidney Health Dis) - "This case demonstrates the potential for sucroferric oxyhydroxide use to result in poor bowel preparation and resulting inadequate visualization on lower gastrointestinal endoscopy. It serves to highlight the clinical implications leading to the need for repeated procedures, which contributes to resource waste and unnecessary costs to the healthcare system, as well as delays in diagnostic evaluation required for transplantation; patient frustration was evident."

Journal • Chronic Kidney Disease • Gastroenterology • Gastrointestinal Disorder • Metabolic Disorders • Nephrology • Oncology • Renal Disease • Transplantation

Management of serum phosphorus over a 1-year follow-up in patients on peritoneal dialysis prescribed sucroferric oxyhydroxide as part of routine care: a retrospective analysis. (PubMed, BMC Nephrol) - "Patients on PD who were prescribed SO as part of routine care for phosphorus management experienced significant reductions in SP and PB pills per day and improvements in sP target achievement, suggesting the effectiveness of SO on SP management with a concurrent reduction in pill burden."

Journal • Retrospective data • Chronic Kidney Disease • Metabolic Disorders • Nephrology • Renal Disease

Efficacy and safety of sucroferric oxyhydroxide versus sevelamer carbonate: a systematic review and meta-analysis (ERA-EDTA 2024) - "This meta-analysis found that sucroferric oxyhydroxide and sevelamer carbonate are equally effective in controlling serum phosphorus and i-PTH levels. Sucroferric oxyhydroxide, however, demonstrated a more favorable profile regarding gastrointestinal adverse events. Our findings suggest sucroferric oxyhydroxide as a valuable alternative for RRT patients who have difficulty tolerating sevelamer carbonate."

Retrospective data • Review • Atherosclerosis • Cardiovascular • Chronic Kidney Disease • Dyslipidemia • Gastrointestinal Disorder • Hypertension • Metabolic Disorders • Nephrology • Renal Disease

The effectiveness and safety of sucroferric oxyhydroxide in the treatment of hyperphosphatemia in dialysis patients: a systematic review (ERA-EDTA 2024) - "The most widely used phosphate binders are sevelamer and lanthanum carbonate. Sucroferric oxyhydroxide is comparable with sevelamer and lanthanum in decreasing serum phosphorus levels. It is also associated with higher hemoglobin, ferritin, and transferrin saturation levels compared with the sevelamer group. Since there are no significant differences in the risks of adverse events, serious adverse events, and all-cause mortality, the decrease in pill burden with sucroferric oxyhydroxide may help improve patient compliance."

Clinical • Review • Gastrointestinal Disorder • Metabolic Disorders • Nephrology • Renal Disease

Iron Storm: A Rare Twist in Sucroferric Oxide Therapy (NKF-SCM 2024) - "Sucroferric oxyhydroxide (SO), an iron-based phosphate binder, is known for its efficacy with a lower daily pill burden... To the best of our knowledge, this is the first reported case of iron overload caused by an iron-based phosphate binder. While rare, it is important to remember that SO can lead to iron overload and end organ damage secondary to this."

Genetic Disorders • Hematological Disorders • Hepatology • Metabolic Disorders • Nephrology • Renal Disease

Investigating Pamidronate's role in the treatment of Calciphylaxis (NKF-SCM 2024) - "Medical history otherwise significant for eosinophilic granulomatosis with polyangiitis treated with rituximab and later cyclophosphamide, and calciphylaxis on prior skin biopsy within 1 year of kidney replacement therapy. He was treated with sodium thiosulfate (STS) 25g thrice weekly, cinacalcet 60mg daily, sucroferric oxyhydroxide 1000mg with meals, and calcitriol... Alternative therapies that augment the calcium-phosphorous axis should be considered in patients with difficult to treat calciphylaxis."

Calciphylaxis • Dermatology • Endocrine Disorders • Eosinophilic Granulomatosis With Polyangiitis • Glomerulonephritis • Immunology • Langerhans Cell Histiocytosis • Metabolic Disorders • Pain • Rare Diseases • Vasculitis

Effectiveness of sucroferric oxyhydroxide (SO) in lowering serum phosphorus in hemodialysis (HD) patients with type 2 diabetes: one-year historical cohort study (NKF-SCM 2024) - "HD pts with type 2 diabetes who started SO as a first line binder or switched to SO from non-SO PB experienced reductions in sP and increases in % pts with sP ≤5.5mg/dL and sP ≤4.5mg/dL, with a mean pill burden of 4-5 pills/day."

Clinical • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Tenapanor (Xphozah) for hyperphosphatemia in chronic kidney disease. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Chronic Kidney Disease • Gastrointestinal Disorder • Metabolic Disorders • Nephrology • Renal Disease